Team Select Scales AI Platform To Full Census, Reports 15% Drop In Hospitalizations
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

  • Thousands of audiobooks, podcasts and originals
  • Listen on your phone, tablet or Echo — also offline
  • Cancel anytime
Try Audible free Free trial for new members
As an affiliate, we earn on qualifying purchases.

Team Select Home Care says its CareSight AI platform now covers all of its patients through respiratory, cardiac and infection models. Company data show hospitalizations fell 14.9% year over year from April through August 2026; the figures have not been independently verified in the source report.

Team Select Home Care says its CareSight AI platform now covers 100% of its patient census and that hospitalizations among its patients fell 14.9% year over year between April and August 2026. The Phoenix-based provider shared the outcome figures with Home Health Care News, but the results are company data and the source report does not describe an independent audit.

CareSight uses more than a decade of Team Select patient records, monitoring up to eight vital signs alongside nurse notes and reported changes in a patient’s condition. The company says the system is designed to identify clinical patterns that may signal a decline and prompt clinicians to respond. Its three current models focus on respiratory conditions, cardiac conditions and infections; Team Select says each patient is covered by at least one.

The rollout began with a respiratory model in 2025. According to President and CEO Fred Johnson, Team Select then added a cardiac model and an infection model after reviewing which conditions and comorbidities accounted for hospitalizations. Johnson told Home Health Care News that the respiratory model took three years to develop, the cardiac model six months, and the infection model 90 days. The company attributed the faster development of later models partly to data preparation and lessons from the first version.

Team Select also adjusted how the platform generates alerts. Johnson said early versions produced too many false positives, including alerts for vital-sign readings that were unusual against general parameters but normal for a particular patient. The company added patient-specific comparisons against historical baselines to reduce those alerts. The report does not provide detailed counts of alerts, false positives or clinician responses.

At a glance
reportWhen: Outcome data cover April–August 2026; f…
The developmentTeam Select says it has expanded its CareSight AI platform to cover its full patient census and reports a year-over-year fall in hospitalizations.

How Coverage Could Shape Home Care

The reported decline could matter to patients and payers because avoiding an admission may reduce disruption for medically complex people receiving care at home, while also affecting health care costs. Team Select serves medically complex children and seniors and operates in 16 states. The company is using its reported outcomes to support discussions about value-based contracts, in which payment can be tied to measures such as hospitalization rates or total cost of care.

Johnson said the platform could help Team Select distinguish itself from competitors and strengthen its case when payers resist fee-for-service rate increases. Those are the company’s expectations, not confirmed contract results: the source report does not identify new agreements or quantify savings associated with CareSight. The hospitalization figures may be relevant to negotiations, but they alone do not establish that the software caused the decline.

Products Worth Considering

As an affiliate, we earn on qualifying purchases.

From Respiratory Model to Full Census

Team Select launched CareSight in 2025 using its historical patient data. The company first concentrated on respiratory patients, then expanded to cardiac patients. Johnson said the two models together covered 65% of patients before Team Select added infection detection. The latest expansion brings reported coverage to the full census, rather than showing that every patient receives the same model or monitoring intensity.

Before CareSight, a seven-state Medicaid claims study commissioned by Team Select found a monthly 30-day hospitalization rate of 3% to 8% for the company, Johnson said. He compared that with an industry range of 10% to 20% per month. The report does not give the study’s full methodology or an independent source for the industry comparison. Team Select had also invested in developing its predictive platform, describing a $6 million commitment to the project. Private equity firm Court Square Capital Partners invested in the company in 2023.

“I knew that if we could do this, not only would it be a long-lasting competitive advantage … [it] would significantly decrease those hospitalizations even further.”

— Fred Johnson, Team Select Home Care president and CEO, speaking to Home Health Care News

Limits of the Reported Results

The 14.9% decline compares April through August 2026 with the same months in 2025, according to company data. The source report does not provide the underlying patient counts, hospitalization totals, statistical analysis or a comparison group. It also does not establish how much of the change, if any, was caused by CareSight rather than other changes in care, patient mix or outside conditions.

The report does not specify whether the platform’s full-census coverage means continuous monitoring for every patient, nor does it give model-level results for respiratory, cardiac and infection alerts. The announced fourth model is still being developed, and its capabilities and launch timing have not been reported.

A Diabetes Model in Development

Team Select is building a fourth CareSight model focused on diabetes, Johnson told Home Health Care News. The report gives no expected completion date or details about how the model will be evaluated. The company also plans to redevelop payer scorecards to show measures including patient satisfaction, hospitalizations and emergency department visits, with comparisons to industry averages, according to Johnson.

Further data on the diabetes model, payer agreements and outcomes across a longer period would help clarify whether the reported decline is sustained and how it relates to the platform’s use. For now, the published result is a five-month, year-over-year comparison provided by Team Select.

Key Questions

What did Team Select report?

Team Select said its CareSight AI platform now covers its full patient census and that hospitalizations fell 14.9% year over year from April through August 2026. The outcome figures come from company data shared with Home Health Care News.

What does CareSight monitor?

The platform uses patient records, nurse notes and changes in condition, and can monitor up to eight vital signs. Team Select says its models address respiratory conditions, cardiac conditions and infections.

Has the reported reduction been independently verified?

The source report presents the hospitalization result as Team Select’s data. It does not describe an independent audit, provide a comparison group or establish that CareSight caused the decline.

What is Team Select developing next?

Johnson said the company is developing a fourth model focused on diabetes. The report does not give a launch date or evaluation results.

Source: rss

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

Novel GIP/GLP-1 Yields Uneven Findings In Diabetes Patients With Obesity

In phase III SYNCHRONIZE-2, survodutide reduced weight and HbA1c in adults with obesity and type 2 diabetes, but GI events led many to stop treatment.

Exercise Linked To Better Attention And Memory After Breast Cancer

A 12-month trial found greater attention gains with exercise among breast cancer survivors, while memory gains at six months did not persist.

Atacicpet, Sibeprenlimab Halt Decline In Kidney Function In IgA Nephropathy

Final phase III results show slower eGFR decline with atacicept and sibeprenlimab versus placebo, supporting efforts to secure full FDA approval.

A Study Spanning 118 Countries Reveals A Divide In Pain And Aging

A study of 6.1 million people finds pain patterns differ by age, sex and country development, with several pain types peaking before age 55.